Observational Study for Lung Cancer

(MYLUNG Trial)

Recruiting at 16 trial locations

Overseen By Taqi Mohammad

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: US Oncology Research

Disqualifiers: Stage IA, Small cell lung cancer, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 5 years

7500 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand the effectiveness of biomarker-guided therapy for individuals with non-small cell lung cancer. Researchers seek to determine the timing of patient testing, the challenges encountered, and the effectiveness of the treatments. The trial targets those recently diagnosed with early-stage or advanced non-small cell lung cancer who are considering systemic therapy, which targets the whole body. Participants must join the trial within 30 days of starting their treatment. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.

Why are researchers excited about this trial?

The MYLUNG Consortium Part 3: Observational Study is exciting because it aims to deepen our understanding of lung cancer treatment patterns and outcomes. Unlike current treatments that focus primarily on directly targeting cancer cells, this study focuses on gathering real-world data to improve personalized care strategies. Researchers are particularly eager to discover new insights that could lead to more effective and tailored treatment approaches, potentially improving survival rates and quality of life for lung cancer patients. By analyzing diverse patient experiences, the study hopes to uncover trends and predictors that can optimize existing therapies and inform future innovations.

Who Is on the Research Team?

Makenzi C. Evangelist, MD

Principal Investigator

New York Oncology Hematology

Patrick J. Ward, MD

Principal Investigator

Oncology Hematology Care Clinical Trials, LLC

Are You a Good Fit for This Trial?

Inclusion Criteria

Must be eligible for systemic therapy based on the treating provider's assessment. If systemic therapy was recommended and documented by the treating provider but the patient declined, they can still be eligible for the study. Patients can be enrolled prior to start of treatment.

Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease

Subjects must be enrolled within 30 days of initiation of systemic therapy

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Testing and Evaluation

Participants undergo comprehensive biomarker testing to guide treatment decisions

5 years

Treatment

Participants receive biomarker-guided therapy based on testing results

5 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years

What Are the Treatments Tested in This Trial?

Who Is Running the Clinical Trial?

US Oncology Research

Lead Sponsor

Trials

38

Recruited

17,400+